Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy in EGFR-mutated NSCLC
NCT07709585Phase 2Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Nov 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Guangzhou University of Chinese Medicine. Started Nov 2026; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07709585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709585.